advent international considers sale of generic drugmaker zentiva for 5 billion euros

Advent International is reportedly considering selling Zentiva, a generic drugmaker previously owned by Sanofi, for a potential valuation of around €5 billion ($5.4 billion).

The private equity firm, which acquired Zentiva in 2018, is working with Goldman Sachs Group Inc. and PJT Partners to explore strategic options for the business.

Interest in Zentiva is expected to come from various buyout firms and financial investors looking to expand their presence in the pharmaceutical sector. This move reflects the ongoing trend of firms seeking opportunities in the generic drug space.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings